Retatrutide 12mg Retatrutide is a cutting-edge triple agonist research peptide that targets three distinct hormonal receptors: GLP-1, GIP, and the glucagon receptor (GCGR)
Am J Prev Cardiol
If the results are as strong as TRIUMPH-4 suggests, Lilly could potentially seek priority review, which would shorten the timeline by several months
2 In 2024, the approved commercial versions of semaglutide are Ozempic 3-4 , Rybelsus 3,5 , and Wegovy injection 3,6 , developed by Novo Nordisk
However, semaglutides share is projected to decline to 37% by 2035, as tirzepatide emerges as the new market leader
In Phase 2 clinical trials, gastrointestinal side effects like nausea (28% of patients) and diarrhea (24%) peaked at weeks 6-8, then substantially resolved by week 12